# KEYNOTE-170 (NCT02576990)

> Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: relapsed or refractory primary mediastinal large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02576990
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Mediastinal Large B-cell Lymphoma; Richter Syndrome
- Interventions: Pembrolizumab
- Enrollment: 80
- Primary outcome: Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review

## Indexed commentary on KEYNOTE-170 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-170-nct02576990

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02576990", "email": "<work email>"}; the inbox owner confirms by the emailed link.